2022
Survival in male breast cancer over the past 3 decades
Leone J, Freedman R, Leone J, Tolaney S, Vallejo C, Leone B, Winer E, Lin N, Hassett M. Survival in male breast cancer over the past 3 decades. Journal Of The National Cancer Institute 2022, 115: 421-428. PMID: 36583555, PMCID: PMC10086618, DOI: 10.1093/jnci/djac241.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalMale breast cancerOverall survivalBreast cancerMultivariable Cox regressionCancer-specific survivalEnd Results registryYear of diagnosisBreast cancer mortalityStage of diseaseLog-rank testCox regressionCancer mortalityKaplan-MeierIndependent associationCox modelSignificant improvementSignificant associationCancerLife expectancyDiagnosisSurvivalSignificant differencesPatientsMen191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026)
Hennessy M, Leal J, Huang C, Solnes L, Denbow R, Abramson V, Carey L, Liu M, Rimawi M, Specht J, Storniolo A, Valero V, Vaklavas C, Winer E, Krop I, Wolff A, Cimino-Mathews A, Wahl R, Stearns V, Connolly R. 191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026). Annals Of Oncology 2022, 33: s623-s624. DOI: 10.1016/j.annonc.2022.07.226.Peer-Reviewed Original Research
2013
Differences in psychosocial factors among diverse women enrolled in a phase III cooperative group metastatic breast cancer trial (CALGB 40502/Alliance).
Polite B, Allred J, Rugo H, Cipriano T, Cirrincione C, Gehlert S, Paskett E, Hudis C, Winer E. Differences in psychosocial factors among diverse women enrolled in a phase III cooperative group metastatic breast cancer trial (CALGB 40502/Alliance). Journal Of Clinical Oncology 2013, 31: 9581-9581. DOI: 10.1200/jco.2013.31.15_suppl.9581.Peer-Reviewed Original ResearchMetastatic breast cancer trialsBreast cancer trialsCancer trialsRace/ethnicitySocial supportBreast cancer patientsLower overall survivalLow social supportAfrican American womenSocio-demographic factorsOverall survivalHispanic patientsCancer patientsHigh comorbiditySelf-identified race/ethnicityPsychosocial factorsSelf-administered surveyPatientsLow levelsMarital statusEthnic differencesSurvivalTrialsComorbiditiesAmerican women
2012
Survival Implications Associated with Variation in Mastectomy Rates for Early‐Staged Breast Cancer
Brooks JM, Chrischilles EA, Landrum MB, Wright KB, Fang G, Winer EP, Keating NL. Survival Implications Associated with Variation in Mastectomy Rates for Early‐Staged Breast Cancer. International Journal Of Surgical Oncology 2012, 2012: 127854. PMID: 22928097, PMCID: PMC3423912, DOI: 10.1155/2012/127854.Peer-Reviewed Original ResearchEarly-stage breast cancerMastectomy ratesESBC patientsRCT populationBreast cancerSurvival implicationsHealth Consensus Development ConferenceHigher mastectomy ratesConsensus Development ConferenceSurgery choicePatientsMastectomyDevelopment ConferenceNIH guidelinesNational InstituteRecent evidenceRCTsCancerBreastSurvivalPatient alignmentGuidelinesSurgeryPopulation
2008
Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival
Bafford AC, Burstein HJ, Barkley CR, Smith BL, Lipsitz S, Iglehart JD, Winer EP, Golshan M. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Research And Treatment 2008, 115: 7-12. PMID: 18581232, DOI: 10.1007/s10549-008-0101-7.Peer-Reviewed Original ResearchConceptsStage IV breast cancerOverall survivalBreast cancerStage IV breast carcinomaMedian overall survivalDatabase of patientsAdverse predictorsHer2neu statusUnderwent mastectomySurgery groupLiver metastasesMedian survivalMetastatic diseaseBreast surgeryTherapeutic surgeryBreast carcinomaNS groupRetrospective analysisStaging factorsSurgerySurvivalWomenPatientsMultivariate survivalCancer
1999
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
Kantoff P, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer E, Vogelzang N. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. Journal Of Clinical Oncology 1999, 17: 2506-13. PMID: 10561316, DOI: 10.1200/jco.1999.17.8.2506.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate cancerTreatment failureDisease progressionPain controlSurvival durationProstate cancerResults of treatmentOverall survivalPalliative optionMore frequent responsesPatientsHydrocortisoneLife parametersNew drugsCancerMitoxantroneProgressionSurvivalDiseasePossible benefitsMenTreatmentFrequent responseFailureDuration